Artivion (NYSE:AORT) Announces Earnings Results, Misses Estimates By $0.51 EPS

Artivion (NYSE:AORT) released its quarterly earnings data on Monday. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51), reports. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Artivion updated its FY 2025 guidance to EPS.

Artivion Price Performance

Shares of NYSE AORT traded down $3.49 during mid-day trading on Tuesday, hitting $24.36. 496,490 shares of the stock traded hands, compared to its average volume of 354,995. The firm has a 50 day simple moving average of $29.75 and a two-hundred day simple moving average of $27.83. Artivion has a twelve month low of $18.38 and a twelve month high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The company has a market cap of $1.02 billion, a PE ratio of -1,223.30 and a beta of 1.75.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on AORT shares. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Stifel Nicolaus decreased their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC decreased their price objective on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Oppenheimer upped their price objective on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $31.40.

Insider Activity at Artivion

In other news, CAO Amy Horton sold 4,329 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the transaction, the chief accounting officer now directly owns 135,660 shares of the company’s stock, valued at $4,023,675.60. The trade was a 3.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jean F. Holloway sold 8,070 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total value of $243,068.40. Following the completion of the sale, the senior vice president now owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. This represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 20,017 shares of company stock worth $600,007 in the last quarter. 8.10% of the stock is owned by insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.